The drug discovery and development process is complex, time-consuming and costly. Traditional methods rely on trial-and-error, extensive laboratory experiments, and iterative optimization to identify and synthesize viable drug candidates.
You need a software platform that can help you accelerate the design/make/test/analyze (DMTA) process with fewer and faster cycles. EvolvePK+ is an AI-driven drug design platform that helps you generate millions of virtual candidates daily by simultaneously optimizing activity, synthesizability, ADMET, and—unlike any other tools currently available—PK/tissue selectivity properties.
No other platform can provide this level of confidence in your drug candidates.
